SAB Biotherapeutics (SABS) Total Current Liabilities (2020 - 2026)
SAB Biotherapeutics' (SABS) quarterly Total Current Liabilities came in at $9.9 million in Q1 2026, up 2.06% YoY from $9.7 million in Q1 2025, and down 7.76% on a QoQ basis from $10.7 million in Q4 2025.
SAB Biotherapeutics (SABS) Total Current Liabilities (2020 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 7 years of Total Current Liabilities data on file, last reported at $9.9 million in Q1 2026.
- Quarterly Total Current Liabilities rose 2.06% year-over-year to $9.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.9 million (up 2.06% YoY) and the FY2025 annual result came in at $10.7 million, up 33.86% from the prior year.
- Total Current Liabilities slipped to $9.9 million in Q1 2026, from $10.7 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $19.3 million in Q1 2022 to a low of $7.6 million in Q2 2024.
- A 5-year average of $11.6 million and a median of $10.7 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 23988.3% — and 2023, when it tumbled 46.14%.
- Tracing SABS's Total Current Liabilities over 5 years: stood at $15.0 million in 2022, then decreased by 27.88% to $10.8 million in 2023, then declined by 26.21% to $8.0 million in 2024, then soared by 33.86% to $10.7 million in 2025, then slipped by 7.76% to $9.9 million in 2026.
- The last three Total Current Liabilities figures came in at $9.9 million (Q1 2026), $10.7 million (Q4 2025), and $10.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - | 11.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.71 Mn |
| Mar 31, 2026 | 9.85 Mn |
| Dec 31, 2025 | 10.68 Mn |
| Sep 30, 2025 | 10.79 Mn |
| Jun 30, 2025 | 10.68 Mn |
| Mar 31, 2025 | 9.65 Mn |
| Dec 31, 2024 | 7.98 Mn |
| Sep 30, 2024 | 8.82 Mn |
| Jun 30, 2024 | 7.55 Mn |
| Mar 31, 2024 | 8.30 Mn |
| Dec 31, 2023 | 10.81 Mn |
| Sep 30, 2023 | 9.21 Mn |
| Jun 30, 2023 | 11.01 Mn |
| Mar 31, 2023 | 13.67 Mn |
| Dec 31, 2022 | 14.99 Mn |
| Sep 30, 2022 | 17.10 Mn |
| Jun 30, 2022 | 16.39 Mn |
| Mar 31, 2022 | 19.27 Mn |
| Dec 31, 2021 | 26.46 Mn |
| Sep 30, 2021 | 322,376.00 |